<--- Back to Details
First PageDocument Content
Health / Niemann-Pick disease /  type C / NPC1 / Niemann–Pick disease / Ara Parseghian / Epididymal secretory protein E1 / Lysosomal storage disease / Cyclodextrin / Cholesterol / Lipid storage disorders / Chemistry / Rare diseases
Date: 2013-10-14 15:50:46
Health
Niemann-Pick disease
type C
NPC1
Niemann–Pick disease
Ara Parseghian
Epididymal secretory protein E1
Lysosomal storage disease
Cyclodextrin
Cholesterol
Lipid storage disorders
Chemistry
Rare diseases

FALL[removed]For Friends and Supporters of the Ara Parseghian Medical Research Foundation Dear Friends, It has been an extremely busy summer and we have much to be grateful for.

Add to Reading List

Source URL: www.parseghian.org

Download Document from Source Website

File Size: 2,08 MB

Share Document on Facebook

Similar Documents

How one patient with a rare disease coped with his genetic disorder

How one patient with a rare disease coped with his genetic disorder

DocID: 1r9mW - View Document

CrossMark_Color_flat+click

CrossMark_Color_flat+click

DocID: 1r0lC - View Document

What is  HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive

What is HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive

DocID: 1lIxr - View Document

MUCOPOLYSACCHARIDOSES  Rare Diseases Unit of the Finnish Association of People with Physical Disabilities  Support for this guide was provided by Genzyme.

MUCOPOLYSACCHARIDOSES Rare Diseases Unit of the Finnish Association of People with Physical Disabilities Support for this guide was provided by Genzyme.

DocID: 1fJSQ - View Document

May 27, 2014  BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

DocID: 1aiEg - View Document